Asuragen, Inc. Release: Results of a Multi-Center Study Show MicroRNA-Based Pancreatic Cancer Assay Improves the Diagnostic Accuracy of FNA Cytology
AUSTIN, Texas--(BUSINESS WIRE)--Asuragen, Inc. announced today that data from a multi-center study evaluating its microRNA-based test, miRInform™ Pancreas, for the diagnosis of pancreatic ductal adenocarcinoma (PDAC) in fine needle aspirates, was presented as a Poster of Distinction at the American Pancreatic Association (APA) Annual Meeting being held November 2-5, 2011 in Chicago.